Next Article in Journal
Plantar Pressure and Contact Area Measurement of Foot Abnormalities in Stroke Rehabilitation
Previous Article in Journal
The Effect of Cannabis-Based Medicine on Neuropathic Pain and Spasticity in Patients with Multiple Sclerosis and Spinal Cord Injury: Study Protocol of a National Multicenter Double-Blinded, Placebo-Controlled Trial
Review

Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease

by 1,2 and 1,*
1
Department of Pharmacology, Wonkwang University School of Medicine, Iksan 54538, Korea
2
Department of Rehabilitation, Affiliated Hospital of Jiujiang University, Jiujiang 332000, China
*
Author to whom correspondence should be addressed.
Academic Editor: Basavaraj S. Balapal
Brain Sci. 2021, 11(9), 1211; https://doi.org/10.3390/brainsci11091211
Received: 17 August 2021 / Revised: 3 September 2021 / Accepted: 4 September 2021 / Published: 14 September 2021
(This article belongs to the Section Neurodegenerative Diseases)
Alzheimer’s disease (AD), the most common neurodegenerative disease, is characterized by progressive cognitive impairment. The deposition of amyloid beta (Aβ) and hyperphosphorylated tau is considered the hallmark of AD pathology. Many therapeutic approaches such as Food and Drug Administration-approved cholinesterase inhibitors and N–methyl–D–aspartate receptor antagonists have been used to intervene in AD pathology. However, current therapies only provide limited symptomatic relief and are ineffective in preventing AD progression. Cannabidiol (CBD), a phytocannabinoid devoid of psychoactive responses, provides neuroprotective effects through both cannabinoid and noncannabinoid receptors. Recent studies using an AD mouse model have suggested that CBD can reverse cognitive deficits along with Aβ-induced neuroinflammatory, oxidative responses, and neuronal death. Furthermore, CBD can reduce the accumulation of Aβ and hyperphosphorylation of tau, suggesting the possibility of delaying AD progression. Particularly, the noncannabinoid receptor, peroxisome proliferator-activated receptor gamma, has been suggested to be involved in multiple functions of CBD. Therefore, understanding the underlying mechanisms of CBD is necessary for intervening in AD pathology in depth and for the translation of preclinical studies into clinical settings. In this review, we summarize recent studies on the effect of CBD in AD and suggest problems to be overcome for the therapeutic use of CBD. View Full-Text
Keywords: Alzheimer’s disease; cannabidiol; cannabinoid receptor; endocannabinoid system; amyloid β; phosphorylated tau Alzheimer’s disease; cannabidiol; cannabinoid receptor; endocannabinoid system; amyloid β; phosphorylated tau
Show Figures

Figure 1

MDPI and ACS Style

Xiong, Y.; Lim, C.-S. Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease. Brain Sci. 2021, 11, 1211. https://doi.org/10.3390/brainsci11091211

AMA Style

Xiong Y, Lim C-S. Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease. Brain Sciences. 2021; 11(9):1211. https://doi.org/10.3390/brainsci11091211

Chicago/Turabian Style

Xiong, Yinyi, and Chae-Seok Lim. 2021. "Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease" Brain Sciences 11, no. 9: 1211. https://doi.org/10.3390/brainsci11091211

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop